文献速递临床试验与 GCP基础与转化研究

靶向DNAJ-PKAc的治疗性肽疫苗用于纤维板层型肝细胞癌:一项1期试验

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
PubMed 文献 · Nat Med · 2025-11-24

这项1期临床试验在既往未接受免疫检查点治疗的晚期纤维板层型肝细胞癌儿童和成人中,评估靶向DNAJ-PKAc的肽疫苗(FLC-Vac)联合纳武利尤单抗和伊匹木单抗的安全性与T细胞反应。16例入组患者中12例完成疫苗启动阶段并可评估免疫和临床终点,中位年龄24岁(范围12-47岁),6例(37.5%)报告3级治疗相关不良事件;12例中9例检测到DNAJ-PKAc特异性T细胞反应,该亚组疾病控制率为75%(9/12),其中部分缓解3例(25%)。

要点

  • 16例晚期FLC患者入组,12例完成疫苗启动阶段并可评估免疫与临床终点。
  • 6例(37.5%)报告3级治疗相关不良事件。
  • 12例中9例检测到DNAJ-PKAc特异性T细胞反应,该亚组疾病控制率75%(9/12),部分缓解3例(25%)。

核心结论

  • 靶向「不可成药」致癌驱动因子的治疗性疫苗具有潜力,并提出了评估有效抗新抗原免疫的框架。

研究设计与样本

  • 1期临床试验,纳入既往未接受免疫检查点治疗的晚期FLC儿童和成人,给予靶向DNAJ-PKAc的肽疫苗(FLC-Vac)联合纳武利尤单抗和伊匹木单抗。
  • 主要目标为第10周后(启动阶段)的安全性和T细胞反应。
  • 16例患者入组,其中12例完成疫苗启动阶段并可评估免疫学和临床终点;中位年龄24岁(范围12-47岁)。

主要发现

  • 6例患者(37.5%)报告3级治疗相关不良事件。
  • 12例中9例在治疗后检测到DNAJ-PKAc特异性T细胞反应。
  • 完成初始启动阶段的患者亚组疾病控制率为75%(9/12),其中部分缓解3例(25%)。
  • 所有临床缓解患者均有DNAJ-PKAc特异性T细胞反应,并从中鉴定出多个具有DNAJ-PKAc特异性的II类限制性T细胞受体。
  • 缓解相关因素包括功能性新抗原反应性和T细胞受体库特征随时间的变化;两例患者的免疫逃逸与免疫耗竭相关,而非新抗原逃逸或人类白细胞抗原丢失。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer affecting children and young adults that is driven by a chimeric protein, DNAJ-PKAc. The development of molecular inhibitors of DNAJ-PKAc has been hampered by unacceptable on-target toxicity, but the chimera results in a tumor-specific antigen (neoantigen) that may be targeted immunologically. Here we conducted a phase 1 clinical trial of a therapeutic peptide vaccine targeting DNAJ-PKAc (FLC-Vac), in combination with nivolumab and ipilimumab, in children and adults with advanced FLC, who had not previously received immune checkpoint therapy. The primary objectives were safety and T cell responses after week 10 (priming phase). Of the 16 patients enrolled, 12 completed the vaccine priming phase and were evaluable for both immunological and clinical endpoints. The median age was 24 years (range 12-47 years). Grade 3 treatment-related adverse events were reported by six patients (37.5%). DNAJ-PKAc-specific T cell responses were detected in 9 of 12 patients after treatment. In the subset of patients who completed the initial priming phase the disease control rate was 75% (9/12), with three partial responses (25%). All patients with clinical responses also had DNAJ-PKAc-specific T cell responses, from which we identified multiple class-II-restricted T cell receptors with specificity for DNAJ-PKAc. Correlates of response included both functional neoantigen reactivity and changes in T cell receptor repertoire features over time. Immune escape in two patients corresponded with immune exhaustion rather than neoantigen escape or human leukocyte antigen loss. Our findings demonstrate the potential for therapeutic vaccines targeting 'undruggable' oncogenic drivers and suggest a rubric for evaluating effective anti-neoantigen immunity. ClinicalTrials.gov identifier: NCT04248569 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Baretti M, Kirk AM, Ladle BH, et al. A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial. Nat Med. 2025. PMID: 41286513. doi:10.1038/s41591-025-03995-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。